The FDA clarifies that both Mounjaro single-dose vial products, which were approved in July 2023 (supplement to NDA 215866), and Zepbound single-dose vials, which were approved in March 2024 (supplement to NDA 217806), never appeared on the shortage list
Very helpful At first, I thought it would be hard giving myself a shot, but the video helps you a lot
Another factor driving a leveling off of effectiveness is that dosing for semaglutide drugs must be precisely tailored to individual patients
Early observational data suggests that patients on GLP-1 therapy for weight loss may see B12 levels decline by 10-15% over six to twelve months, depending on baseline status and dietary intake
Reported side effects are rare and typically mild temporary redness or irritation at the application site, usually resolving quickly No documented systemic toxicity in research literature at typical therapeutic doses European Medicines Agency and independent research groups rate it as well-tolerated Compatible with most standard skincare routines when used with appropriate spacing from incompatible actives Contraindications and cautions Known sensitivity or allergy to copper compounds: avoid use Active skin infections or open wounds at the injection site: delay treatment Pregnancy and breastfeeding: insufficient safety data
Our goal isn't just to help you lose the weight it's to make sure you never have to lose it again
